Solumedrol

ApprovedSmall molecule

Solumedrol is one of 230 small molecule programs targeting Systemic Inflammatory Response Syndrome. It is currently in Approved.

Indications

Total Trials

Active Trials

229

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Inflammatory Response SyndromeActive, not recruiting

LymphomaActive, not recruiting

SepsisActive, not recruiting

Juvenile Idiopathic ArthritisActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Acute Respiratory Distress SyndromeActive, not recruiting

Secondary Progressive Multiple SclerosisActive, not recruiting

Systemic Inflammatory Response SyndromeApproved

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

SepsisApproved

Active, not recruiting

Juvenile Idiopathic ArthritisPhase 3

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

Acute Respiratory Distress SyndromePhase 2

Active, not recruiting

Secondary Progressive Multiple SclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Solumedrol

SStanford University

Approved

1 2

Zofran

Novartis

Preclinical

2 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

PEG-Intron

Merck & Co.

Preclinical

1 8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

Lymphoma

NCT00882895

Clinical

Trials by Indication[1]

Transplantation2 trials

Allogeneic Transplantation From Related Haploidentical Donors

Completed·SStanford University·Phase 2·NCT00185692·16 enrolled

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Completed·SStanford University·Phase 2·NCT00899847·9 enrolled

Lymphoma1 trial

Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT00882895·18 enrolled

Juvenile Idiopathic Arthritis1 trial

The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis

Recruiting·SSohag University·Phase 3·NCT06463379·215 enrolled

Systemic Inflammatory Response Syndrome1 trial

Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome

Completed·—·Phase 4·NCT03876041·60 enrolled

Acute Lymphoblastic Leukemia1 trial

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00671658·220 enrolled

6 more indications

Ablation1 trial

Corticosteroid Pulse After Ablation

Completed·MMinneapolis Heart Institute Foundation·Phase 4·NCT00807586·119 enrolled

Acute Respiratory Distress Syndrome1 trial

Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome

Completed·NNational Taiwan University Hospital·Phase 2·NCT01423864·29 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis

Terminated·UUniversity of Utah·N/A·NCT02296346·13 enrolled

Prevention1 trial

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Completed·SStanford University·Phase 2·NCT00186628·36 enrolled

Rheumatoid Arthritis1 trial

Pulse Steroid Injection in Refractory Rheumatoid Arthritis

Recruiting·SSohag University·Phase 3·NCT06456489·268 enrolled

Sepsis1 trial

Adrenal Cortical Function and Vitamin A Deficiency in Sepsis

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT03152474·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Solumedrol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Solumedrol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Solumedrol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SStanford University

Solumedrol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Transplantation2 trials

Lymphoma1 trial

Juvenile Idiopathic Arthritis1 trial

Systemic Inflammatory Response Syndrome1 trial

Acute Lymphoblastic Leukemia1 trial

Ablation1 trial

Acute Respiratory Distress Syndrome1 trial

Secondary Progressive Multiple Sclerosis1 trial

Prevention1 trial

Rheumatoid Arthritis1 trial

Sepsis1 trial

References

Drug Info

Quick Facts

Related News